Navidea Biopharmaceuticals Inc (NAVBQ)

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company quoted on OTC Markets under common stock listing NAVB.Q. The company focuses on precision immunodiagnostic agents and immunotherapeutics, with work organized around Diagnostic Substances and Therapeutic Development Programs. Its Manocept platform is designed to target the CD206 mannose receptor on activated macrophages and is being applied across imaging approaches such as single photon emission computed tomography, PET, gamma scanning, and intra-operative or optical-fluorescence detection, as well as in therapies aimed at macrophage-related, immune, and inflammation-related diseases.

The company’s development program includes NAV3-31, NAV3-35, NAV3-33, and NAV3-32, all evaluated in rheumatoid arthritis-related studies at different clinical stages. Navidea is also pursuing Tc99m tilmanocept for potential use in cardiovascular, Kaposi’s sarcoma, tuberculosis, and other immunotherapeutic applications. Incorporated in 1983 and headquartered in Dublin, Ohio, the company was formerly known as Neoprobe Corporation before adopting its current name in 2012. On October 1, 2025, it filed a voluntary Chapter 11 reorganization petition in the U.S. Bankruptcy Court for the District of Delaware.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.